Correction: Recurrent mutations in a  SERPINC1  hotspot associate with venous thrombosis without apparent antithrombin deficiency

Wei Zeng; Bei Hu; Liang Tang; Yan-Yan You; Mara Toderici; Maria Eugenia de la Morena-Barrio; Javier Corral; Yu Hu

doi:10.18632/oncotarget.24519

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Recurrent mutations in a SERPINC1 hotspot associate with venous thrombosis without apparent antithrombin deficiency

PDF | How to cite

Oncotarget. 2018; 9:11428-11428. https://doi.org/10.18632/oncotarget.24519

Metrics: PDF 2447 views | ?

Wei Zeng^1,2,*, Bei Hu^1,*, Liang Tang1^,*, Yan-Yan You³, Mara Toderici⁴, Maria Eugenia de la Morena-Barrio⁴, Javier Corral⁴ and Yu Hu¹

¹ Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
² Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
³ Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
⁴ Centro Regional de Hemodonaciόn, Universidad de Murcia, IMIB, CIBERER, Murcia, Spain
^* These authors contributed equally to this work.

Published: February 16, 2018

This article has been corrected: the 1^st affiliation has been revised.

Original article: Oncotarget. 2017; 8:84417-84425. DOI: https://doi.org/10.18632/oncotarget.21365.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24519

Publication Alerts

Corrections:

Correction: Recurrent mutations in a SERPINC1 hotspot associate with venous thrombosis without apparent antithrombin deficiency